American Society of Clinical Oncology Statement: Biosimilars in Oncology.
Publication
, Journal Article
Lyman, GH; Balaban, E; Diaz, M; Ferris, A; Tsao, A; Voest, E; Zon, R; Francisco, M; Green, S; Sherwood, S; Harvey, RD; Schilsky, RL
Published in: J Clin Oncol
April 20, 2018
As many biosimilars come to market in the next several years, their use in oncology will play an important role in the future care of patients with cancer. ASCO is committed to providing education and guidance to the oncology community on the use of biosimilars in the cancer setting; therefore, ASCO has developed this statement to offer guidance in the following areas: (1) naming, labeling, and other regulatory considerations, (2) safety and efficacy of biosimilars, (3) interchangeability, switching, and substitution, (4) value of biosimilars, and (5) prescriber and patient education.
Duke Scholars
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
April 20, 2018
Volume
36
Issue
12
Start / End Page
1260 / 1265
Location
United States
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Legislation, Drug
- Humans
- Biosimilar Pharmaceuticals
- Antineoplastic Agents
- Adolescent
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Lyman, G. H., Balaban, E., Diaz, M., Ferris, A., Tsao, A., Voest, E., … Schilsky, R. L. (2018). American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol, 36(12), 1260–1265. https://doi.org/10.1200/JCO.2017.77.4893
Lyman, Gary H., Edward Balaban, Michael Diaz, Andrea Ferris, Anne Tsao, Emile Voest, Robin Zon, et al. “American Society of Clinical Oncology Statement: Biosimilars in Oncology.” J Clin Oncol 36, no. 12 (April 20, 2018): 1260–65. https://doi.org/10.1200/JCO.2017.77.4893.
Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, et al. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 Apr 20;36(12):1260–5.
Lyman, Gary H., et al. “American Society of Clinical Oncology Statement: Biosimilars in Oncology.” J Clin Oncol, vol. 36, no. 12, Apr. 2018, pp. 1260–65. Pubmed, doi:10.1200/JCO.2017.77.4893.
Lyman GH, Balaban E, Diaz M, Ferris A, Tsao A, Voest E, Zon R, Francisco M, Green S, Sherwood S, Harvey RD, Schilsky RL. American Society of Clinical Oncology Statement: Biosimilars in Oncology. J Clin Oncol. 2018 Apr 20;36(12):1260–1265.
Published In
J Clin Oncol
DOI
EISSN
1527-7755
Publication Date
April 20, 2018
Volume
36
Issue
12
Start / End Page
1260 / 1265
Location
United States
Related Subject Headings
- United States
- Oncology & Carcinogenesis
- Legislation, Drug
- Humans
- Biosimilar Pharmaceuticals
- Antineoplastic Agents
- Adolescent
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences